Only 11% of Pharma Companies Have Fully Deployed AI in Trials

The AI implementation gap in clinical trials

A new industry survey has quantified what many suspected: the pharmaceutical industry's embrace of artificial intelligence remains largely aspirational. Only 11% of nearly 80 surveyed pharma and biotech companies had fully implemented AI and machine learning to support clinical trial activities as of late 2024, according to WCG's 2026 Clinical Research Trends and Insights Report released this week.

The finding exposes a significant disconnect between industry conversation and operational reality. While conference panels and investor presentations routinely discuss AI as a transformative force in drug development, the vast majority of organizations have yet to move beyond pilot projects or partial deployments.

Why it matters

This implementation gap carries real consequences as regulatory scrutiny intensifies. The FDA issued draft guidance in January 2025 on AI in regulatory decision-making, signaling that sponsors must document, validate, and oversee AI-generated outputs. Companies treating AI as a marketing narrative rather than a governed operational capability now face compliance risk alongside competitive disadvantage.

Four operational pressure points

The WCG report, first detailed by Clinical Trial Vanguard, organizes its analysis around four interconnected themes: AI and ML governance, site and investigator readiness, participant experience, and the operational demands of cell and gene therapies.

On AI governance, the report takes a notably disciplined stance. Rather than celebrating theoretical capabilities, WCG frames AI as an emerging embedded tool that carries serious trust and oversight obligations. Enthusiasm without governance infrastructure has become a liability in the current regulatory environment.

Site readiness presents equally stark challenges. An ICON industry survey from 2025 found that 55% of site respondents reported activation timelines of five months or longer, with 39% indicating those timelines had lengthened compared to two years prior. WCG argues for reframing readiness as a continuous operational asset rather than a pre-trial checklist—a structural distinction with significant implications for sponsors managing complex trial portfolios.

Cell and gene therapy programs amplify every pressure point: longer follow-up windows, specialized logistics, narrow patient populations, and regulatory coordination demands that conventional site networks were not designed to handle.

Participant experience as connective tissue

The report draws a deliberate distinction between participant-centric design—studies built around patient convenience—and participant-driven research, where patient input actively shapes protocol decisions. That difference has direct implications for retention rates and data quality, two variables that regulatory submissions depend on.

WCG identifies a key metric for 2026: whether site activation timelines compress as data-driven readiness assessments replace intuition-based site selection. That compression represents the point where operational theory meets revenue impact for major contract research organizations.

The report positions 2026 not as a year of breakthrough discovery but as a reckoning for organizations that have built preparedness into their infrastructure rather than just their communications. The 11% full-implementation figure suggests the industry has considerable ground to cover before AI adoption matches the intensity of AI discussion.

Details were first reported by Clinical Trial Vanguard, citing the WCG 2026 Clinical Research Trends and Insights Report.